Portfolio & Pipeline
Sachi Nanoligomer™ platform is being utilized to create and test large libraries of immunomodulatory molecules to selectively up- and down-regulate gene expression of intended targets. This has led to identification of best-in-class and first-in-class molecules that can safely boost host immune system.
Unlike terrestrial medicine, survival of space tourists and astronauts depends on personalized and precision countermeasures optimized to reverse adverse health outcomes. Sachi Bioworks has leverage their proprietary Nanoligomer™ discovery engine to rapidly develop key countermeasures to reverse radiation-induced dysfunction in immune, neurodegeneration, etc.
Facile route of administration, ability to cross the blood-brain barrier, strong safety and biodistribution profile, and targeting multiple pathways through gene networks selectively (with minimal off-targeting) opens new avenues for treating neurodegenerative diseases such as Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Multiple Sclerosis (MS), and Creutzfeldt-Jakob disease (CJD) using Sachi's Nanoligomer™ therapeutics.
Sachi's proprietary discovery engine and Nanoligomers™ are used to reversibly and programmably regulate metabolic pathways and biosynthetic gene clusters (BGCs) in range of genetically intractable microbiome species. Nanoligomers offer a novel genetic tool that are capable of facile modulation of key BGCs leading to modulation of key host immune, neurotransmitters (e.g. serotonin, dopamine), and neurotrophic factors to address challenges in mental health and neuropathology.